Chemotherapy and biotherapy-induced hypersensitivity reactions

Journal of Infusion Nursing

Volumn 32, Issue 3, 2009, Pages 157-165

  Van Gerpen, Ruth ^a  

^a Bryan LGH Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMINOPHYLLINE; ASPARAGINASE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CHLORMETHINE; CIMETIDINE; CISPLATIN; CORTICOSTEROID; CREMOPHOR; DIPHENHYDRAMINE; DOCETAXEL; DOPAMINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IBRITUMOMAB TIUXETAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PREDNISONE; PROCARBAZINE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMAL SENSATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIONEUROTIC EDEMA; BIOLOGICAL THERAPY; BRAIN TUMOR; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEST TIGHTNESS; CHILDHOOD CANCER; CHILL; COUGHING; CYTOKINE RELEASE SYNDROME; DELAYED HYPERSENSITIVITY; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSPNEA; ERYTHEMA; FLUSHING; HODGKIN DISEASE; HUMAN; HYPOTENSION; HYPOXIA; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE COMPLEX DISEASE; INCIDENCE; LARYNX EDEMA; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEOPLASM; NOSE CONGESTION; PATIENT CARE; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; REVIEW; RHINITIS; RIGOR; RISK ASSESSMENT; SIDE EFFECT; TACHYCARDIA; THROAT TIGHTNESS; TUNNEL VISION; URTICARIA; VISUAL DISORDER; VOICE CHANGE; VOMITING; WHEEZING; ANAPHYLAXIS; ARTICLE; CLASSIFICATION; DRUG THERAPY; HYPERSENSITIVITY; IMMUNOLOGY; NATIONAL HEALTH ORGANIZATION; NURSING; UNITED STATES;

ANAPHYLAXIS; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; DRUG HYPERSENSITIVITY; DRUG THERAPY; HUMANS; HYPERSENSITIVITY; NATIONAL CANCER INSTITUTE (U.S.); UNITED STATES;

EID: 70349245330     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/NAN.0b013e3181a1a8ae     Document Type: Review

References (53)

1. Weiss RB. Miscellaneous toxicities. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2964-2976.
2. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253-262.
3. Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005;32:1027-1035.
4. Labovich TM. Acute hypersensitivity reactions to chemotherapy. Semin Oncol Nurs. 1999;15:222-231.
5. Lenz H. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601-609.
6. Myers JS. Complications of cancer and cancer treatment. In: Langhorne ME, Fulton JS, Otto SE, eds. Oncology Nursing. 5th ed. St Louis, MO: Mosby; 2007:402-453.
7. Polovich M, White JM, Kelleher LO. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2005.
8. Johnson RF, Peebles RS. Anaphylactic shock: pathophysiology, recognition and treatment. Semin Respir Crit Care Med. 2004;25:695-703.
9. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725-732.
10. Gobel BH. Metabolic emergencies. In: Itano JK, Taoka KN, eds. Core Curriculum for Oncology Nursing. 4th ed. St Louis, MO: Elsevier Saunders; 2005:383-421.
11. Drain KL, Volcheck GW. Preventing and managing drug-induced anaphylaxis. Drug Saf. 2001;24:843-853.
12. Savarese DM, Castells MC. Infusion reactions to systemic chemotherapy. http://www.uptodate.com. Published 2008. Accessed August 9, 2008.
13. Wilkes GM, Barton-Burke M. Oncology Nursing Drug Handbook. Boston, MA: Jones and Bartlett; 2008.
14. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11(suppl 1):37-42.
15. National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events v.3.0. http://ctep.cancer.gov/reporting/ctc.html. Published 2003. Accessed July 6, 2008.
16. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer. 1976;38:1843-1846.
17. Stone HD, DiPiro C, Davis PC, Meyer CF, Wray BB. Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolate-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. J Allergy Clin Immunol. 1998;101:429-431.
18. Elspar® (Asparaginase) product information. http://www.merck.com/ product/usa/pi-circulars/e/elspar/elspar-pi.pdf. Published 2005. Accessed August 9, 2008.
19. Kingsley CD. Hypersensitivity reactions. In: Perry MC, ed. The Chemotherapy Source Book. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:152-173.
20. Weiss RB, Donehower RH, Wiernik PH. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263-1268.
21. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16:3353-3361.
22. Myers JS. Hypersensitivity reaction to paclitaxel: nursing interventions. Clin J Oncol Nurs. 2000;4:161-163.
23. Theis JGW, Liau-Chu M, Chan HSL, Doyle J, Greenberg ML, Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol. 1995;13:2508-2516.
24. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol. 1996;97:42-46.
25. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17:1141-1145.
26. Morgan JS, Adams M, Mason MD. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer. 1994;30A:1205-1206.
27. Cheng E, Cvitkovic E, Wittes RE, Golbey RB. Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer. 1978;42: 2162-2168.
28. Anderson T, Javadpour N, Schilsky R, Barlock A, Young RC. Chemotherapy for testicular cancer: current status of the National Cancer Institute combined modality trial. Cancer Treat Rep. 1979;63:1687-1692.
29. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med. 1981;95:414-420.
30. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin. Br J Cancer. 2003;89:477-481.
31. Sorich J, Taubes B, Wagner A, Hochster H. Oxaliplatin: practical guidelines for administration. Clin J Oncol Nurs. 2004;8:251-256.
32. Glovsky MM, Braunwald J, Opelz G, Alenty A. Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity. J Allergy Clin Immunol. 1976; 57:134-140.
33. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer. 1991;68:22-29.
34. Coyle T, Bushunow P, Winfield J, Wright J, Graziano S. Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. Cancer. 1992;69:2532-2540.
35. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther. 1997;62:225-229.
36. O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol. 1986;4:1262-1269.
37. Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol. 1993;11:1080-1084.
38. Reiger PT, Green M, Murray L. Monoclonal antibodies: applications in solid tumors and other diseases. In: Rieger PT, ed. Biotherapy. Sudbury, MA: Jones and Bartlett; 2001:317-355.
39. Wilkes GM. Chemotherapy and biotherapy. In: Gobel BH, Triest-Robertson S, Vogel WH, eds. Advanced Oncology Nursing Certification Review and Resource Manual. Pittsburgh, PA: Oncology Nursing Society; 2008:149-185.
40. Oncology Education Services, Inc. Biomolecular Targeted Therapies in Cancer Treatment [slide kit]. Pittsburgh, PA: Oncology Education Services Inc; 2003.
41. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
42. LaCasce AS, Castells MC, Burstein H, Meyerhardt JA. Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy. http://www.uptodate. com. Published 2008. Accessed August 9, 2008.
43. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007;25:2691-2695.
44. O'Neil BH, Allen R, Spigel DR. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association of atopic history. J Clin Oncol. 2007;25:3644-3648.
45. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244- 3254.
46. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older adults with acute myeloid leukemia in first relapse after Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-1636.
47. Gobel BH. Hypersensitivity reactions to biological drugs. Semin Oncol Nurs. 2007;23:191-200.
48. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110:980-988. (Pubitemid 47312862)
49. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory lowgrade or transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:3918-3928.
50. Cobleigh M, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
51. Carr BW, Burke C. Outpatient chemotherapy: hypersensitivity and anaphylaxis. Am J Nurs. 2001;101(suppl):27-30.
52. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol. 2006;6: 272-277.
53. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist. 2004;9:546-549.